<SEC-DOCUMENT>0001683168-22-005037.txt : 20220719
<SEC-HEADER>0001683168-22-005037.hdr.sgml : 20220719
<ACCEPTANCE-DATETIME>20220719171540
ACCESSION NUMBER:		0001683168-22-005037
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20220719
DATE AS OF CHANGE:		20220719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PharmaCyte Biotech, Inc.
		CENTRAL INDEX KEY:			0001157075
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621772151
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40699
		FILM NUMBER:		221092206

	BUSINESS ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653
		BUSINESS PHONE:		(917) 595.2850

	MAIL ADDRESS:	
		STREET 1:		23046 AVENIDA DE LA CARLOTA, SUITE 600
		CITY:			LAGUNA HILLS
		STATE:			CA
		ZIP:			92653

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVILEX, INC.
		DATE OF NAME CHANGE:	20090324

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EFOODSAFETY COM INC
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>pharmacyte_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>

</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Form 8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Current Report</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported): <FONT STYLE="text-decoration: underline">July
19, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B><FONT STYLE="text-decoration: underline">PHARMACYTE
BIOTECH, INC.</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><FONT STYLE="text-decoration: underline">Nevada</FONT></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><FONT STYLE="text-decoration: underline">001-40699</FONT></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><FONT STYLE="text-decoration: underline">62-1772151</FONT></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3960
    Howard Hughes Parkway, Suite
    500<BR> Las Vegas, Nevada</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 50%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>89169</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Zip Code)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="text-align: center">&#160;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant's telephone number, including area code:
<B>(917) 595-2850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-decoration: underline">N/A</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &#9744; Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &#9746; Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9744; Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title of each class</FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name of exchange on which registered</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Stock, Par Value $0.0001 Per Share</FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">PMCB</FONT></TD>
    <TD>&#160;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Nasdaq
Stock Market LLC</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this Chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 73px"><B>Item 8.01</B></TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt"><B> Other Events.</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July 19, 2022, PharmaCyte
Biotech, Inc. (&#8220;PharmaCyte&#8221; or the &#8220;Company&#8221;) issued a press release providing an update with respect to its Malignant
Ascites Program. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Important Additional Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, its directors and certain of its
executive officers are participants in the solicitation of proxies from the Company&rsquo;s shareholders in connection with the Company&rsquo;s
2022 Annual Meeting of Stockholders. The Company intends to file a definitive proxy statement and a WHITE proxy card with the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) in connection with any such solicitation of proxies from the Company&rsquo;s stockholders.
STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT, ACCOMPANYING WHITE PROXY CARD AND ALL OTHER DOCUMENTS
FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. The Company&rsquo;s
definitive proxy statement for the 2022 Annual Meeting of Stockholders will contain information regarding the direct and indirect interests,
by security holdings or otherwise, of the Company&rsquo;s directors and executive officers in the Company&rsquo;s securities. Information
regarding subsequent changes to their holdings of the Company&rsquo;s securities can be found in the SEC filings on Forms 3, 4, and 5,
which are available on the Company&rsquo;s website at https://ir.pharmacyte.com/all-sec-filings or through the SEC&rsquo;s website at
www.sec.gov. Information can also be found in the Company&rsquo;s Annual Report on&nbsp;Form 10-K&nbsp;for the year ended April 30, 2022
to be filed with the SEC and in subsequent filings with the SEC. Updated information regarding the identity of potential participants,
and their direct or indirect interests, by security holdings or otherwise, will be set forth in the definitive proxy statement and other
materials to be filed with the SEC in connection with the 2022 Annual Meeting of Stockholders. Stockholders will be able to obtain the
definitive proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC
at no charge at the SEC&rsquo;s website at www.sec.gov. Copies will also be available at no charge at the Company&rsquo;s website at https://ir.pharmacyte.com/all-sec-filings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 73px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits. </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Exhibits.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 73px; font-size: 10pt"><FONT STYLE="font-size: 10pt"><FONT STYLE="text-decoration: underline">Number</FONT></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><FONT STYLE="text-decoration: underline">Description</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A HREF="pharmacyte_ex9901.htm">Press Release, dated July 19, 2022, of PharmaCyte Biotech, Inc.</A></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">104</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&#160;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: July 19, 2022</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>PHARMACYTE BIOTECH, INC.</B></FONT></TD></TR>
  <TR>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&#160;</TD>
    <TD STYLE="white-space: nowrap; width: 1%"><FONT STYLE="font-size: 10pt">By:&#160;&#160;&#160;</FONT></TD>
    <TD STYLE="width: 48%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: underline">/s/ Kenneth L. Waggoner</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kenneth L. Waggoner</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and General Counsel</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&#160;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&#160;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>



</BODY>
</HTML>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pharmacyte_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>PharmaCyte Biotech
Reports Positive Interim Results in Malignant Ascites Mouse Model Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LAS VEGAS, NV, July 19, 2022&mdash;(BUSINESS WIRE)&mdash;PharmaCyte
Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites
using its signature live-cell encapsulation technology, Cell-in-a-Box<SUP>&reg;</SUP>, announced today that it has achieved positive interim
results in its study to establish a malignant ascites mouse model which will form the basis for further testing of the effectiveness of
its CypsCapsTM plus ifosfamide pancreatic cancer therapy for the treatment of malignant ascites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The study is being conducted by Heidelberg Pharma, a leading German
biotechnology company focused on cancer therapies, using colon carcinoma cells from a Master Cell Bank established by Austrianova implanted
in genetically susceptible mice. Primary objectives include establishing parameters with respect to (i) optimum tumor cell inoculation
dose; (ii) timing curve with respect to tumor growth; and (iii) the most accurate method to assess tumor burden. The last point is particularly
important because it provides a gauge to measure the effectiveness of therapeutic interventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">Initial data in the study indicate that a measure of overall
tumor volume is likely a more accurate way of tracking tumor burden when compared to measuring labeled tumor cell fluorescence. Tumor
volume in the study is being reported using an adaptation of the Sugarbaker-index. The Sugarbaker-index is a widely used and accepted
quantitative prognostic indicator for patients with malignant ascites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">PharmaCyte&rsquo;s Chief Executive Officer, Kenneth L. Waggoner,
said, &ldquo;We are highly encouraged that Heidelberg Pharma&rsquo;s work with this study to establish a malignant ascites mouse model
is proceeding exactly as we had hoped and that it has yielded valuable information as we work diligently to advance our therapy for malignant
ascites. We are confident that all our objectives in this study will be achieved. We will continue to keep our shareholders informed as
work progresses at Heidelberg Pharma.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">Malignant ascites is caused by an accumulation of fluid in
the peritoneum causing the abdomen to swell as a result of cancer. It is often associated with ovarian, uterine, cervical, colorectal,
stomach, pancreatic, breast and liver cancers. Malignant ascites can result in significant impairment to the quality of life of a cancer
patient and reduce survival. Currently, available treatments are mainly supportive and palliative. In most patients, development of malignant
ascites is a sign of advanced disease and poor prognosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PharmaCyte expects its treatment to offer cancer patients a therapy
that slows down or eliminates the production and accumulation of malignant ascites fluid. There is currently no such treatment on the
market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To learn more about PharmaCyte&rsquo;s pancreatic cancer treatment
and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company&rsquo;s
documentary video complete with medical animations at:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: blue">https://www.PharmaCyte.com/Cancer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About PharmaCyte Biotech</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">PharmaCyte Biotech, Inc. is a biotechnology company developing
cellular therapies for cancer, diabetes and malignant ascites based upon a proprietary cellulose-based live-cell encapsulation technology
known as &ldquo;Cell-in-a-Box<SUP>&reg;</SUP>.&rdquo; This technology is being used as a platform upon which therapies for several types
of cancer, diabetes and malignant ascites are being developed. PharmaCyte&rsquo;s therapy for cancer involves encapsulating genetically
engineered human cells that convert an inactive chemotherapy drug into its active or &ldquo;cancer-killing&rdquo; form. For pancreatic
cancer, these encapsulated cells are implanted in the blood supply to the patient&rsquo;s tumor as close as possible to the site of the
tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the
normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide
flows through pores in the capsules, the live cells inside act as a &ldquo;bio-artificial liver&rdquo; and activate the chemotherapy drug
at the site of the cancer. This &ldquo;targeted chemotherapy&rdquo; has proven effective and safe to use in past clinical trials and we
believe results in little to no treatment related side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">PharmaCyte&rsquo;s candidate therapy for Type 1 diabetes
and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce and release
insulin in response to the levels of blood sugar in the human body. The encapsulation of the cell line will be done using the Cell-in-a-Box<SUP>&reg;</SUP>
technology. Once the encapsulated cells are implanted in a diabetic patient, we anticipate that they will function as a &ldquo;bio-artificial
pancreas&rdquo; for purposes of insulin production.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">PharmaCyte&rsquo;s therapy for malignant ascites involves
using the same encapsulated cells PharmaCyte employs for pancreatic cancer but placing the encapsulated cells in the peritoneal cavity
of a patient and administering ifosfamide intravenously.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Safe Harbor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">This press release may contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of PharmaCyte&rsquo;s
management and Board of Directors. Any statements contained in this press release which do not describe historical facts are forward-looking
statements subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from
those discussed in such forward-looking statements. Factors that could affect our actual results include our ability to satisfactorily
address the issues raised by the FDA in order to have the clinical hold on our IND removed, as well as such other factors that are included
in the periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. These forward-looking
statements are made only as of the date hereof, and we undertake no obligation to update or revise the forward-looking statements, except
as otherwise required by law, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.05in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0.1in; margin-bottom: 0pt">More information about PharmaCyte Biotech can be found at <FONT STYLE="color: blue">https://www.PharmaCyte.com<U>.</U></FONT>
Information may also be obtained by contacting PharmaCyte's Investor Relations Department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Investor
Relations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">PharmaCyte
Biotech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Telephone:
917.595.2856</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Email: <FONT STYLE="color: blue">InvestorRelations@PharmaCyte.c</FONT><FONT STYLE="color: #0462C1"><U>om</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Attn: Dr.
Gerald W. Crabtree</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  [ .$# 2(  A$! Q$!_\0
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1@^@J6DHN]@LD[A1112 __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
